ORGS
Orgenesis Inc.
Key Financials
Gross Profit
$-893000
↑ 84.4%
Operating Income
$-39768000
↑ 25.9%
Net Income
$-48165000
↑ 13.0%
Revenue
$1.0M
↑ 95.3%
EPS (Diluted)
$11.44
↑ 499.0%
Total Assets
$1.4M
↓ 90.7%
Shareholders' Equity
$-37501000.00
↓ 78.7%
Total Liabilities
$38.9M
↑ 9.4%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 6/2/2026 | View on SEC |
| DEFR14A | 5/20/2026 | View on SEC |
| DEF 14A | 5/5/2026 | View on SEC |
| PRE 14A | 4/16/2026 | View on SEC |
| 10-K | 3/26/2026 | View on SEC |
| 8-K | 3/13/2026 | View on SEC |
| 8-K | 1/26/2026 | View on SEC |
| 8-K | 9/16/2025 | View on SEC |
| 8-K | 8/25/2025 | View on SEC |
| 8-K | 8/19/2025 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ORGS |
| Company Name | Orgenesis Inc. |
| CIK | 1460602 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | NV |
| Phone | (480) 659-6404 |